Table 3.

Susceptibilities of Candida strains to fluconazole, P-113, and Nal-P-113 in modified LYM medium

Candida sp.	Source	Strain	MIC (μg/ml)
			Fluconazole	Control		50 mM NaCl		100 mM NaCl		150 mM NaCl
				P-113	Nal	P-113	Nal	P-113	Nal	P-113	Nal
C. krusei	ATCC 6258	YLO6	32	6.25	6.25	6.25	6.25	100	6.25	100	12.5
C. parapsilosis	ATCC 22019	YLO7	8	6.25	6.25	50	12.5	>100	12.5	>100	25
C. glabrata	ATCC 9003	YLO8	16	12.5	6.25	>100	25	>100	25	>100	25
C. albicans	ATCC 90028	YLO12	1	6.25	6.25	25	12.5	100	12.5	>100	12.5
C. tropicalis	ATCC 13803	YLO86	>64	3.1	6.25	3.1	6.25	12.5	6.25	12.5	6.25
C. albicans	HIV patient	YH050001	2	6.25	6.25	25	12.5	100	12.5	>100	12.5
C. albicans	HIV patient	YH050005	1	6.25	6.25	50	25	>100	25	>100	25
C. tropicalis	HIV patient	YH050007	>64	3.1	6.25	3.1	6.25	25	6.25	25	12.5
C. tropicalis	HIV patient	YH050013	>64	3.1	6.25	3.1	6.25	50	6.25	50	12.5
C. albicans	HIV patient	YH050072	>64	6.25	6.25	25	25	>100	25	>100	25
C. krusei	HIV patient	YH050075	64	6.25	6.25	25	12.5	>100	12.5	>100	12.5
C. dubliniensis	HIV patient	YH050092	0.5	6.25	6.25	12.5	12.5	>100	12.5	>100	12.5
C. glabrata	HIV patient	YH050105	16	6.25	6.25	50	12.5	100	25	>100	50
C. tropicalis	HIV patient	YH050114	>64	3.1	6.25	3.1	6.25	100	6.25	100	12.5